Introduction {#s1}
============

Idiopathic hypogonadotropic hypogonadism (IHH) is comprised of absent puberty, infertility and low serum gonadotrophins in the absence of a pituitary tumor. IHH is due to impaired gonadotrophin releasing hormone (GnRH) release/action or gonadotrophin secretion. Kallmann syndrome (KS) consists of IHH with anosmia. KS appears to be the result of impairment of GnRH and olfactory neuron migration from the olfactory placode to the hypothalamus ([@GAN027C2]).

Mutations in genes involved in GnRH neuron migration (KAL1 and FGFR1), as well as those expressed in either the hypothalamus or pituitary, including GNRHR, NROB1, GPR54, LEP, LEPR and PCSK1 account for the molecular etiology of ∼15--20% of all IHH/KS patients ([@GAN027C11]; [@GAN027C7]; [@GAN027C14]; [@GAN027C2]; [@GAN027C18]). Three genes---KAL1, GNRHR and FGFR1---account for the majority of causative mutations. The molecular basis for most IHH/KS cases, however, remains unknown. Digenic disease has been reported in two families with FGFR1 and either a GNRHR or a NELF mutation ([@GAN027C15]).

Most mutations identified in genetic diseases, including IHH/KS, are point mutations and small deletions/duplications detected by PCR-based DNA sequencing ([@GAN027C13]). PCR based sequencing may not detect heterozygous gene deletions, however, since the remaining normal allele will be amplified. Therefore, it is possible that a substantial number of mutations remain undiagnosed.

Multiplex ligation-dependent probe amplification (MLPA) is a relatively new method for detecting copy number variations in genomic sequences ([@GAN027C17]). MLPA involves overnight hybridization of adjacent primer pairs to the individual exons of multiple target genes simultaneously, followed by a ligation reaction of the probe pairs, which then serve as a template for multiplex PCR. Each ligated probe has a varying length of 'stuffer' sequences that produce different sized fragments for resolution based upon size ([@GAN027C17]). Since all probes have identical primer binding sites, only a single primer pair is required for multiplex PCR of all genes being studied.

Heterozygous intragenic deletions have been found in 15--20% of patients with cystic fibrosis ([@GAN027C1]), deafness ([@GAN027C9]) and breast/ovarian cancer ([@GAN027C12]) who did not have point mutations in the corresponding genes. We hypothesized that a similar percentage of IHH/KS patients would have heterozygous deletions of autosomal genes (FGFR1, GNRH1, GNRHR, GPR54 or NELF) and/or hemizygous KAL1 gene deletions, deletions which would be missed by the traditional PCR-based sequencing methods. Additionally, since KAL1 has a pseudogene homolog on the Y chromosome, this may complicate the DNA sequencing analysis ([@GAN027C8]).

Materials and Methods {#s2}
=====================

Patients {#s2a}
--------

One-hundred and twelve probands with IHH/KS were studied by MLPA (Table [I](#GAN027TB1){ref-type="table"}). The diagnosis of IHH was based upon criteria published previously---absent/impaired puberty by age ≥17 in girls and age ≥18 in boys, low serum gonadotrophins, no evidence of a pituitary tumor and otherwise normal pituitary function ([@GAN027C6]; [@GAN027C4]). All males had total testosterone \<100 ng/dl (normal 300--1100 ng/dl), and all females had hypoestrogenic amenorrhea. Complete IHH was defined as absent breast development in females and testicular size ≤3 ml in males ([@GAN027C4]). Incomplete IHH suggested the presence of prior steroid production and was defined as breast development of Tanner ≥2 in females and testis size \>3 ml in males. Patient characteristics are shown in Table [I](#GAN027TB1){ref-type="table"}. The Medical College of Georgia Human Assurance Committee approved this study; each patient signed informed consent.

###### 

Classification of patients by gene(s) tested.

  KAL1 Kit         KAL2 Kit   KAL1&KAL2 Kits   Total Patients Studied                                          
  ---------------- ---------- ---------------- ------------------------ ---------------- ---- ---------------- -----
  **Male**         45         **Male**         72                       **Male**         38   **Male**         79
  Anosmic/Hypos    33         Anosmic/Hypos    37                       Anosmic/Hypos    26   Anosmic/Hypos    44
  Normosmic        12         Normosmic        18                       Normosmic        12   Normosmic        18
  Unknown          0          Unknown          17                       Unknown          0    Unknown          17
  Complete IHH     13         Complete IHH     15                       Complete IHH     10   Complete IHH     18
  Incomplete IHH   20         Incomplete IHH   19                       Incomplete IHH   18   Incomplete IHH   21
  Unknown          12         Unknown          38                       Unknown          10   Unknown          40
  **Female**       9          **Female**       28                       **Female**       4    **Female**       33
  Anosmic/Hypos    7          Anosmic/Hypos    7                        Anosmic/Hypos    3    Anosmic/Hypos    11
  Normosmic        2          Normosmic        10                       Normosmic        1    Normosmic        11
  Unknown          0          Unknown          11                       Unknown          0    Unknown          11
  Complete IHH     3          Complete IHH     7                        Complete IHH     2    Complete IHH     8
  Incomplete IHH   2          Incomplete IHH   6                        Incomplete IHH   0    Incomplete IHH   8
  Unknown          4          Unknown          15                       Unknown          2    Unknown          17
  **Totals**       54         **Totals**       100                      **Totals**       42   **Totals**       112
  Anosmic/Hypos    40         Anosmic/Hypos    44                       Anosmic/Hypos    29   Anosmic/Hypos    55
  Normosmic        14         Normosmic        28                       Normosmic        13   Normosmic        29
  Unknown          0          Unknown          28                       Unknown          0    Unknown          28
  Complete IHH     16         Complete IHH     22                       Complete IHH     12   Complete IHH     26
  Incomplete IHH   22         Incomplete IHH   25                       Incomplete IHH   18   Incomplete IHH   29
  Unknown          16         Unknown          53                       Unknown          12   Unknown          57

Fifty-four patients were studied for the presence of KAL1 deletions (KAL1 kit) and 100 IHH/KS patients were studied for deletions of an autosomal panel of FGFR1, GNRH1, GNRHR, GPR54 and NELF genes (KAL2 kit). We estimated that we needed a sample size of ∼50 for study of KAL1 gene deletions, since the prevalence of mutations is about 6% in anosmic males ([@GAN027C5]). The sample size for the autosomal gene panel (KAL2 kit) was estimated to be ∼100. The prevalence of FGFR1 mutations in both normosmic IHH and KS is about 10% ([@GAN027C14]), whereas GNRHR mutations occur in 3--4% of normosmic IHH ([@GAN027C3]). This sample should allow detection if they occur in this frequency. The prevalence of GNRH1, NELF and GPR54 mutations in IHH and KS is currently unknown, but is probably low. By screening ∼100 patients, we could determine if the prevalence was at least 1%.

KAL1 gene deletions were studied in 45 males and nine females. Since KAL1 mutations have been exclusively identified in anosmic/hyposmic patients, the majority of patients studied (40/54) were anosmic/hyposmic. All patients were randomly selected from available DNA samples without regard to prior mutation analysis from our large IHH/KS cohort.

Molecular analysis/MLPA {#s2b}
-----------------------

DNA was extracted from white blood cells in all IHH/KS using standard methods. MLPA was performed in patients according to Schouten ([@GAN027C17]; [@GAN027C12]). A total of 125 ng of DNA was hybridized overnight to the probe sets of the commercially available kits. The P132 KAL1 kit (MRC Holland, Amsterdam, Netherlands) contains 34 probe pairs for all 14 KAL1 exons and control sequences for other regions on Xp, Xq and Yq11. The P133 KAL2 kit contains 39 probe pairs covering the following exons of autosomal genes: GNRH1 (exons 1--3 of 4 exons), GNRHR (exons 1--3 of 3 exons), GPR54 (exons 1, 4 and 5 of 5 exons), FGFR1 (1--3, 5, 6, 8,10,13,14 and 18 of 18 exons) and NELF (exons 5, 11 and 15 of 16 exons). These probes also include control sequences on chromosomes 1--3, 6, 11, 15--17, 19, 20 and Y.

Following hybridization, a ligation reaction was performed which served as a template for 35 cycles of multiplex PCR using universal primers. PCR products were analyzed on an ABI 310 autoanalyzer using the Gene Scan program and data were evaluated using Genotyper 2.0 (both from Applied Biosystems, Foster City, CA, USA). Peak areas for each exon were converted into an Excel file and the relative copy number of each fragment was compared to the same fragments from 2 to 3 controls. MLPA was repeated at least three times for patients with putative deletions. Deletions were confirmed by PCR and DNA sequencing ([@GAN027C5]).

Results {#s3}
=======

Using MLPA for the KAL1 gene, deletions were identified in 4/54 (7.4%) patients and in 4/40 (10%) of anosmic/hyposmic patients (Table [II](#GAN027TB2){ref-type="table"}). When only anosmic males were considered, KAL1 deletions were present in 4/33 (12.1%). Three whole gene deletions were detected, as indicated by absence of peaks for each exon (Fig. [1](#GAN027F1){ref-type="fig"}). All three whole gene deletions were confirmed by the absence of bands by PCR. In one of these patients, deletion of exons 1--13 had previously been identified ([@GAN027C5]); however, DNA sequencing of exon 14 was consistent with pseudogene sequence, thereby confirming the whole gene deletion by MLPA. One patient had an exon 4 deletion (Fig. [1](#GAN027F1){ref-type="fig"}) which, upon DNA sequencing, revealed a 3 bp deletion (TGT) of codon 164, deleting a Cys (Cys164del) rather than the deletion of the entire exon. No heterozygous/homozygous deletions were identified in the FGFR1, GNRH1, GNRHR, GPR54 or NELF genes in 100 IHH/KS patients.

![MLPA results demonstrating.\
(**A**) The KAL1 exon 4 deletion; (**B**) whole KAL1 gene deletion; (**C**) normal control. Arrows indicate the deleted exons. The horizontal axis (top) shows the size of the fragment in base pairs. A difference in relative copy peak height or peak area indicates a copy number change of the probe target sequence.](gan02701){#GAN027F1}

###### 

Summary of KAL1 exon/gene deletions.

  Deletion type   Sex        Smell      IHH severity   Family history/comments
  --------------- ---------- ---------- -------------- ---------------------------
  Whole Gene      **Male**   Anosmic    Incomplete     None
  Whole Gene      **Male**   Hyposmic   Complete       Visual Field abnormality
  Whole Gene      **Male**   Anosmic    Complete       Two first cousins with KS
  Exon 4          **Male**   Anosmic    Incomplete     Renal Agenesis

Discussion {#s4}
==========

The genetic basis of IHH/KS has been identified in 15--20% of patients, most commonly in KAL1, GNRHR or FGFR1 genes ([@GAN027C2]). KAL1 mutations have been identified in anosmic males---approximately 5% of KS males without a family history and 30--70% of those with clear X-linked recessive inheritance ([@GAN027C5]). GNRHR mutations cause autosomal recessive IHH in ∼3--5% of IHH patients, all of whom are normosmic ([@GAN027C3]). Interestingly, FGFR1 mutations occur in ∼10% of anosmic or normosmic patients ([@GAN027C14]).

Nearly all mutations in these genes are point mutations or small deletions/insertions. In contrast, only a very few gross deletions been identified in IHH/KS candidate genes. Available prevalence studies likely underestimate IHH/KS gene deletions as traditional PCR-based DNA sequencing is unable to detect heterozygous gene deletions. Therefore, it is possible that a substantial number of mutations remain undiagnosed. Using MLPA, heterozygous intragenic deletions have been found in 15--20% of patients with cystic fibrosis ([@GAN027C1]), deafness ([@GAN027C9]) and breast/ovarian cancer ([@GAN027C12]) who did not have point mutations.

MLPA is an effective technique used to detect genomic deletions and duplications ([@GAN027C17]). If probe pairs for individual exons are utilized, MLPA can successfully determine the relative copy number of all exons within gene/genes simultaneously. MLPA has gained acceptance in genetic diagnostic laboratories due to its simplicity, relatively low cost and capacity for reasonably high throughput analysis. MLPA has a variety of applications in addition to detection of deletions/duplications. Other important uses include aneuploidy detection ([@GAN027C10]), analysis of DNA methylation ([@GAN027C16]), relative mRNA quantification ([@GAN027C20]), chromosomal characterization of cell lines and tissue samples ([@GAN027C21]) and the detection of polymorphisms ([@GAN027C19]).

The frequency of gene deletions in IHH/KS candidate genes has not been previously reported. We hypothesized that MLPA would identify intragenic deletions in ∼15--20% of IHH/KS patients. Using MLPA, we discovered that 7.4% of 54 patients had KAL1 deletions. If only anosmic males were considered, 4/33 (12.1%) had KAL1 deletions. Three patients had whole gene deletions---one of which was previously described by PCR to be deleted of exons 1--13 ([@GAN027C5]). PCR and DNA sequencing subsequently confirmed a whole gene deletion in this patient. MLPA also revealed one subject who appeared to have a deletion of exon 4. In this case, DNA sequencing revealed a 3 bp deletion rather than an entire exon deletion. It is likely that the probe pair did not specifically anneal to the template of exon 4, therefore, no ligation and subsequent PCR could be performed ([@GAN027C17]). Our findings indicate that putative deletions indicate identified by MLPA requires confirmation by another technique.

We also used MLPA to screen for heterozygous intragenic deletions of five autosomal genes---FGFR1, GNRH1, GNRHR, GPR54 and NELF. Surprisingly, no deletions were identified in 100 IHH/KS patients. Probe pairs were dispersed across the coding regions of these genes, affording the opportunity to detect intragenic deletions. Only three exons were studied for the NELF gene, but at the time that this kit was designed, no NELF mutations had been described. We cannot exclude that intragenic deletions of exons not included in the kits occur, which would underestimate the prevalence of intragenic gene deletions. Nevertheless, no deletions of any of the five autosomal genes were identified in 100 IHH/KS patients.

Although the prevalence of deletions in IHH/KS in autosomal genes was much less than that expected, the prevalence of KAL1 deletions approximated 10--15% that we hypothesized. The findings from this pilot study demonstrate the feasibility of MLPA to detect deletions in IHH/KS and suggest the benefits of future studies with an increased sample size of IHH/KS.
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